dc.contributor.author |
Buchanan, Christina |
en |
dc.contributor.author |
Lee, Kathryn |
en |
dc.contributor.author |
Shepherd, Peter |
en |
dc.date.accessioned |
2020-05-11T23:15:21Z |
en |
dc.date.issued |
2019-08-22 |
en |
dc.identifier.citation |
Biomolecules 9(9) 22 Aug 2019 |
en |
dc.identifier.issn |
2218-273X |
en |
dc.identifier.uri |
http://hdl.handle.net/2292/50622 |
en |
dc.description.abstract |
The hyper-activation of the phosphoinositide (PI) 3-kinase signaling pathway is a hallmark of many cancers and overgrowth syndromes, and as a result, there has been intense interest in the development of drugs that target the various isoforms of PI 3-kinase. Given the key role PI 3-kinases play in many normal cell functions, there is significant potential for the disruption of essential cellular functions by PI 3-kinase inhibitors in normal tissues; so-called on-target drug toxicity. It is, therefore, no surprise that progress within the clinical development of PI 3-kinase inhibitors as single-agent anti-cancer therapies has been slowed by the difficulty of identifying a therapeutic window. The aim of this review is to place the cellular, tissue and whole-body effects of PI 3-kinase inhibition in the context of understanding the potential for dose limiting on-target toxicities and to introduce possible strategies to overcome these. |
en |
dc.format.medium |
Electronic |
en |
dc.language |
eng |
en |
dc.relation.ispartofseries |
Biomolecules |
en |
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. |
en |
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
en |
dc.rights.uri |
https://creativecommons.org/licenses/by/4.0/ |
en |
dc.subject |
Animals |
en |
dc.subject |
Humans |
en |
dc.subject |
Neoplasms |
en |
dc.subject |
Protein Transport |
en |
dc.subject |
Dose-Response Relationship, Drug |
en |
dc.subject |
Phosphatidylinositol 3-Kinases |
en |
dc.subject |
Phosphoinositide-3 Kinase Inhibitors |
en |
dc.title |
For Better or Worse: The Potential for Dose Limiting the On-Target Toxicity of PI 3-Kinase Inhibitors. |
en |
dc.type |
Journal Article |
en |
dc.identifier.doi |
10.3390/biom9090402 |
en |
pubs.issue |
9 |
en |
pubs.volume |
9 |
en |
dc.rights.holder |
Copyright: The authors |
en |
pubs.publication-status |
Published |
en |
dc.rights.accessrights |
http://purl.org/eprint/accessRights/OpenAccess |
en |
pubs.subtype |
Research Support, Non-U.S. Gov't |
en |
pubs.subtype |
review-article |
en |
pubs.subtype |
Review |
en |
pubs.subtype |
Journal Article |
en |
pubs.elements-id |
782677 |
en |
pubs.org-id |
Medical and Health Sciences |
en |
pubs.org-id |
Medical Sciences |
en |
pubs.org-id |
Molecular Medicine |
en |
pubs.org-id |
Science |
en |
pubs.org-id |
Science Research |
en |
pubs.org-id |
Maurice Wilkins Centre (2010-2014) |
en |
dc.identifier.eissn |
2218-273X |
en |
pubs.record-created-at-source-date |
2019-08-25 |
en |
pubs.dimensions-id |
31443495 |
en |